"A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study" by W. Kenneth Washburn

Selected Works of Thomas Heffron, MD, FACS

Article

A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study

Liver Transplantation (2006)

W. Kenneth Washburn, University of Texas Health Science Center at San Antonio
Lewis W. Teperman, New York University
Thomas G. Heffron, Emory University
David D. Douglas, Mayo Clinic
Eliezer Katz, CTI Clinical Trial and Consulting Services
Goran B.G. Klintmalm, Baylor University Medical Center

Link

Disciplines

Medicine and Health Sciences,
Gastroenterology,
Surgery,
Hepatology and
Internal Medicine

Publication Date

April 1, 2006

DOI

10.1002/LT.20631

Citation Information

W. Kenneth Washburn, Lewis W. Teperman, Thomas G. Heffron, David D. Douglas, et al.. "A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study" Liver Transplantation Vol. 12 Iss. 4 (2006) p. 585 - 591
Available at: http://works.bepress.com/thomas-heffron/19/